Stock TAK TAKEDA PHARMACEUTICAL COMPANY LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

All News Takeda Pharmaceutical Company Limited Nyse

Equities

TAK

US8740602052

Market Closed - Nyse
Other stock markets
 21:00:02 24/06/2024 BST 		5-day change 1st Jan Change
12.88 USD +2.22% Intraday chart for Takeda Pharmaceutical Company Limited -2.20% -9.74%
06-24 Hutchmed China notes Takeda obtains EU approval for Fruzaqla AN
06-24 Takeda's Organ Transplant Infection Treatment Approved by Japan Regulators MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Hutchmed China notes Takeda obtains EU approval for Fruzaqla
AN
Takeda's Organ Transplant Infection Treatment Approved by Japan Regulators
MT
Hutchmed (China), Takeda Secure EU Approval for Colorectal Cancer Treatment
MT
Takeda Announces Approval of LIVTENCITY® (maribavir) in Japan for Post-Transplant Cytomegalovirus (CMV) Infection/Disease That Is Refractory to Existing Anti-CMV Therapies
BU
Takeda Announces Approval of LIVTENCITY® by the Japanese Ministry of Health, Labour and Welfare
CI
Japanese Shares End Higher as BoJ Indicates Readiness for Policy Shifts
MT
Takeda Receives European Commission Approval for Colorectal Cancer Treatment
MT
Takeda Receives European Commission Approval for FRUZAQLA® (fruquintinib)
CI
Takeda Presents Late-Breaking Data from Phase 2b Study of Mezagitamab, Demonstrating Potential to Transform Treatment of Primary Immune Thrombocytopenia
BU
Takeda Presents Late-Breaking Data from Phase 2b Study of Mezagitamab, Demonstrating Potential to Transform Treatment of Primary Immune Thrombocytopenia
CI
Takeda Secures European Commission's Approval for Colorectal Cancer Drug Fruzaqla
MT
Takeda Pharmaceutical Gets European Commission Approval for Cancer Treatment
DJ
Takeda Receives Approval from European Commission for FRUZAQLA in Previously Treated Metastatic Colorectal Cancer
BU
Takeda Receives Approval from European Commission for Fruquintinib in Previously Treated Metastatic Colorectal Cancer
CI
Takeda's HyQvia® Approved as Replacement Therapy for Primary Humoral Immunodeficiency and Secondary Humoral Immunodeficiency in Pediatric Patients 2 years of Age and Older
AQ
Japanese Stocks End Little Changed After Three-Day Winning Streak on Inflation and Yen Woes
MT
Takeda gives Sun Pharma, Cipla rights to commercialize gastro drug in India
RE
Sun Pharma Signs Deal with Japan's Takeda to Commercialize Vonoprazan in India
MT
Sun Pharma Signs Non-Exclusive Patent Licensing Agreement with Takeda for Introducing Novel Gastrointestinal Drug, Voltapraz in India
CI
Takeda Presents Long-Term Data from Phase 3 ADVANCE-CIDP 3 Clinical Trial of HYQVIA in Patients with Chronic Inflammatory Demyelinating Polyneuropathy at PNS Annual Meeting
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 4502 Stock
  4. TAK Stock
  5. News Takeda Pharmaceutical Company Limited